Keywords: nycomed, pay, up, 620m, veltuzumab, privately-held, danish

Nycomed to pay up to $620M for veltuzumab

Article | 21 July 2008

Privately-held Danish drugmaker Nycomed has entered into a license and collaboration agreement with USA-based Immunomedics for a worldwide license to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Nycomed

Go to company listing